Wegovy tablets vs Mounjaro — an honest side-by-side comparison

# Wegovy tablets vs Mounjaro — an honest side-by-side comparison

Two names dominate conversations about private weight management treatment in the UK right now: Wegovy and Mounjaro. With the MHRA approval of oral Wegovy tablets in June 2026, the comparison has shifted. You are no longer choosing between two injections — you are now choosing between a tablet and an injection, between two different active ingredients, and between two meaningfully different price points.

This guide lays out the honest differences so you can have an informed conversation with your prescriber.

> **Important:** Wegovy tablets and Mounjaro are both prescription-only medicines. Neither should be started, switched between, or stopped without guidance from a qualified healthcare professional. The information here is for general reference only.

—

## The fundamental difference: one drug, two mechanisms

Before comparing anything else, it helps to understand what these medicines actually are.

**Wegovy tablets** contain semaglutide, a GLP-1 receptor agonist. It works by mimicking the GLP-1 hormone your gut naturally produces after eating, signalling to the brain that you are full, slowing gastric emptying, and reducing appetite. The oral tablet form uses a technology called SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) to help the semaglutide survive the digestive environment and be absorbed through the stomach wall.

**Mounjaro** contains tirzepatide, a dual GIP and GLP-1 receptor agonist. It activates two receptors simultaneously — GLP-1 (the same as semaglutide) and GIP (glucose-dependent insulinotropic polypeptide). This dual action is the main reason Mounjaro shows higher average weight loss in clinical trials. GIP receptors in the brain and fat tissue amplify the appetite-reduction signal, giving tirzepatide a mechanism that semaglutide cannot fully replicate.

Mounjaro does not exist as a tablet. There is no oral tirzepatide approved or commercially available anywhere in the world as of June 2026. If you want a weight management tablet, oral semaglutide (Wegovy) is currently your only option.

—

## Weight loss comparison: what the trials actually showed

Both medicines have robust clinical trial data, but the trials measured different things in different populations — direct comparisons require care.

**Oral Wegovy (OASIS 2 trial):** Participants taking oral semaglutide 25mg achieved an average body weight reduction of 15.1% over 68 weeks. This is a substantial result for an oral medicine — historically, tablets have achieved considerably less than injections for metabolic conditions. The OASIS 2 data established that the tablet form is genuinely therapeutic, not a compromise.

**Mounjaro (SURMOUNT-1 trial):** Participants taking tirzepatide 15mg (the highest dose) achieved an average body weight reduction of approximately 22.5% over 72 weeks. At lower doses, results were lower — 5mg achieved around 15%, and 10mg around 19.5%. The 22.5% figure is the one most commonly cited, and it is a genuine clinical benchmark.

On raw numbers, Mounjaro has the edge. The dual mechanism delivers higher average weight loss. But averages tell only part of the story. Individual response to any GLP-1 treatment varies considerably, some people respond exceptionally well to semaglutide and less so to tirzepatide, and the difference between 15% and 22% average weight loss matters far less if one medicine is well tolerated and the other is not.

—

## Form: the needle question

This is arguably the biggest practical difference for many patients.

Mounjaro is an injection. It is subcutaneous — injected into the fat under the skin of the abdomen, thigh, or upper arm, once weekly using a pre-filled auto-injector pen. Most people who use Mounjaro adapt to the injection quickly, and the auto-injector design makes it relatively straightforward. But for patients who are needle-phobic, or who simply prefer not to self-inject on an ongoing basis, it is a genuine barrier.

Wegovy tablets are swallowed once daily. No needles, no injection sites, no sharps disposal. The daily dose routine — taking the tablet first thing in the morning, waiting 30 minutes before eating or drinking anything other than a small amount of plain water — requires discipline. But for many people, that is a much more manageable daily habit than weekly injections.

The form factor also has a practical implication for discretion. A blister pack of tablets is considerably less conspicuous to carry or store than injectable pens, which require careful handling and, in some cases, refrigeration.

—

## Frequency: daily vs weekly

Wegovy tablets are taken once daily. Mounjaro is injected once weekly.

Neither is objectively better — both are simply different habit patterns. Some people prefer a daily routine because it fits naturally into their morning. Others prefer the set-and-forget nature of a once-weekly injection. If you are someone who already takes a daily tablet (for blood pressure, cholesterol, or any other condition), adding oral Wegovy to that routine is often described as seamless. If daily routines feel onerous, Mounjaro’s weekly schedule may suit you better.

—

## Cost: a significant gap at lower doses

Price is one of the areas where Wegovy tablets offer a substantial advantage, particularly at the starting dose.

**Wegovy tablets:** As of June 2026, UK providers with verified pre-orders open are pricing the 1.5mg starting dose between £64 per month (Bolt Pharmacy) and £113.95 per month (Pharmacy2U). Delivery is free with most tier-1 providers. This is the price for the starting dose — the maintenance dose (25mg) may be priced differently by providers as supply scales.

**Mounjaro:** Private pricing in the UK varies by provider and dose. At the 2.5mg starting dose, costs typically begin around £159 per month. At the higher maintenance doses (10mg or 15mg), private costs can reach £200–£268 per month. The dose escalation in Mounjaro — from 2.5mg to 5mg to 7.5mg, 10mg, 12.5mg, and 15mg — means monthly costs increase significantly over time.

The cost difference is material. Over 12 months, a patient reaching Mounjaro’s higher doses could be paying £2,000–£3,000 more per year than someone on oral Wegovy at a mid-range UK provider. Budget is a legitimate clinical consideration — a treatment you can sustain financially is more effective than one you cannot.

—

## Availability: Mounjaro is more established

Mounjaro (tirzepatide) received MHRA approval for type 2 diabetes in 2022 and for weight management in 2023. It has been commercially available in the UK for private weight management patients since 2023 and has a longer established supply chain.

Oral Wegovy received MHRA approval on 11 June 2026, with commercial launch expected in July 2026. As of the time of writing, pre-orders are open with seven verified UK providers, but stock is arriving in phases. Patients who want to start immediately are more likely to find consistent supply with Mounjaro at the moment, though this is expected to change as oral Wegovy supply stabilises.

—

## NHS access

**Mounjaro:** Tirzepatide is available on the NHS in some specialist weight management services (Tier 3 services), typically for patients with a BMI of 40 or above and significant comorbidities. Access varies significantly by region, and NHS waiting lists for these services can be long.

**Wegovy tablets:** As of June 2026, oral semaglutide is not available on the NHS. NICE guidance covering injectable semaglutide does not automatically extend to the tablet form. Any access to Wegovy tablets is currently via private prescription only.

If NHS access is important to you, Mounjaro may be your only realistic route — though it will depend on your local NHS service.

—

## Side effects: broadly similar profiles

Both medicines share a similar GI side effect profile: nausea, vomiting, diarrhoea, constipation, and stomach discomfort are the most commonly reported effects for both, particularly during dose escalation. Neither is “easier” in this respect than the other in any clear clinical sense.

Mounjaro may cause injection site reactions — redness, bruising, or mild discomfort at the injection point. These are generally minor but are an additional consideration not present with tablets.

Oral Wegovy has its own inconvenience: the fasting requirement. Taking the tablet at least 30 minutes before any food, drink (other than 120ml of plain water), or other oral medicines is non-negotiable for absorption. For some people, particularly those who take morning medications, this requires careful planning.

Both medicines carry the same contraindications for thyroid tumour history and pregnancy. Your prescriber will assess suitability for either treatment as part of a proper clinical evaluation.

—

## Who is each treatment best suited to?

**Wegovy tablets may be a better fit if:**
– You are needle-phobic or strongly prefer not to inject
– Budget is a significant consideration
– You are new to GLP-1 treatments and want to start with the more accessible option
– You already have a daily tablet routine and can incorporate oral Wegovy naturally
– You want to avoid injection site management

**Mounjaro may be a better fit if:**
– Maximising weight loss potential is your primary goal and you are comfortable with injections
– You are already established on a weekly injection routine
– You want a once-weekly rather than daily treatment
– You have NHS access via a specialist weight management service
– Cost is less of a deciding factor

—

## Can you switch between them?

Switching from one to the other is possible but should always be done under prescriber guidance. These are different medicines with different mechanisms and different dose units — there is no automatic dose equivalence between oral semaglutide and tirzepatide. A prescriber will advise on the appropriate starting dose when switching and may recommend a washout period depending on your circumstances.

Do not switch between weight management medicines without a clinical conversation.

—

## Frequently asked questions

### Which one causes more weight loss — Wegovy tablets or Mounjaro?

In clinical trials, Mounjaro (tirzepatide) at its highest dose showed higher average weight loss: approximately 22.5% in the SURMOUNT-1 trial versus 15.1% for oral Wegovy (semaglutide) at 25mg in the OASIS 2 trial. However, individual results vary considerably, and the right choice depends on your clinical profile, not trial averages alone.

### Is there an oral version of Mounjaro?

No. As of June 2026, there is no approved oral tirzepatide anywhere in the world. If you want a weight management tablet, oral Wegovy (semaglutide) is the only currently approved option in the UK.

### Why is Wegovy tablet so much cheaper than Mounjaro?

Pricing reflects multiple factors including dose volume, manufacturing cost, and commercial positioning. At the starting dose, oral Wegovy is priced from £64 per month at verified UK providers, compared to approximately £159 per month for Mounjaro at the entry dose. The gap may narrow at higher doses as oral Wegovy pricing for 25mg tablets is confirmed by providers.

### Can I take Wegovy tablets if I have already tried Mounjaro?

That is a question for your prescriber. Prior treatment with one GLP-1 medication does not automatically disqualify you from another, but your clinical history, response to previous treatment, and current health status will all be relevant to any prescribing decision.

### Does Mounjaro require a fasting window like Wegovy tablets do?

No. Mounjaro injections can be given at any time of day, with or without food. The daily fasting requirement — 30 minutes before food or drink — is specific to the oral semaglutide tablet and relates to how the tablet is absorbed through the stomach wall.

### How do I find verified UK providers for Wegovy tablets?

CompareWegovyPrices.co.uk lists all verified UK providers offering oral Wegovy, including current prices, consultation fees, delivery costs, and availability status. Use the comparison table to find the true first-month cost across providers before making any enquiry.

—

*This article is for informational purposes only and does not constitute medical advice. Wegovy tablets and Mounjaro are both prescription-only medicines available in the UK. Always consult a registered UK healthcare professional before starting, switching, or stopping any weight management treatment. CompareWegovyPrices.co.uk is not affiliated with Novo Nordisk or Eli Lilly.*